Abstract
The extensive use of the same chemotherapeutics over several decades has resulted in a growing incidence of chemoresistant cancer cells and secondary malignancies. Therefore, there is an increasing need for new drugs to treat high-risk cancer patients with a higher selectivity for cancer cells and lower toxicity to normal cells. Sulforaphane is released upon hydrolysis of glucoraphanin, a constituent of cruciferous vegetables, by myrosinases that are present in the plant or intestinal microbes. Despite a large number of studies describing the chemopreventive and chemotherapeutic properties of sulforaphane in solid tumors, there is little information on the properties of sulforaphane in hematological malignancies. In this review, we discuss the anti-carcinogenic properties of sulforaphane, the need of higher doses than dietary intake, and the challenges related to testing sulforaphane as an adjunctive agent in combination with the current standard of care for frontline blood cancer.
Keywords: Animal model, cancer, clinical trial, leukemia, natural product, sulforaphane, therapy.
Current Cancer Drug Targets
Title:From the Table to the Bedside: Can Food-Derived Sulforaphane be used as a Novel Agent to Treat Leukemia?
Volume: 14 Issue: 5
Author(s): Koramit Suppipat and H. Daniel Lacorazza
Affiliation:
Keywords: Animal model, cancer, clinical trial, leukemia, natural product, sulforaphane, therapy.
Abstract: The extensive use of the same chemotherapeutics over several decades has resulted in a growing incidence of chemoresistant cancer cells and secondary malignancies. Therefore, there is an increasing need for new drugs to treat high-risk cancer patients with a higher selectivity for cancer cells and lower toxicity to normal cells. Sulforaphane is released upon hydrolysis of glucoraphanin, a constituent of cruciferous vegetables, by myrosinases that are present in the plant or intestinal microbes. Despite a large number of studies describing the chemopreventive and chemotherapeutic properties of sulforaphane in solid tumors, there is little information on the properties of sulforaphane in hematological malignancies. In this review, we discuss the anti-carcinogenic properties of sulforaphane, the need of higher doses than dietary intake, and the challenges related to testing sulforaphane as an adjunctive agent in combination with the current standard of care for frontline blood cancer.
Export Options
About this article
Cite this article as:
Suppipat Koramit and Lacorazza Daniel H., From the Table to the Bedside: Can Food-Derived Sulforaphane be used as a Novel Agent to Treat Leukemia?, Current Cancer Drug Targets 2014; 14 (5) . https://dx.doi.org/10.2174/1568009614666140521142950
DOI https://dx.doi.org/10.2174/1568009614666140521142950 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Implication of Possible Therapies Targeted for the Tachykinergic System with the Biology of Neurokinin Receptors and Emerging Related Proteins
Recent Patents on CNS Drug Discovery (Discontinued) The Cancer Related Thrombotic Tendency in Sepsis
Current Drug Targets Editorial [Hot Topic: Targeting Tumor Uniquitin-Proteasome Pathway with New and Old Drugs (Guest Editor: Q. Ping Dou)]
Current Cancer Drug Targets Novel Anticancer Targets and Drug Discovery in Post Genomic Age
Current Medicinal Chemistry - Anti-Cancer Agents Functionalized Upconversion Nanoparticles: Versatile Nanoplatforms for Translational Research
Current Molecular Medicine Preliminary Experience with Yttrium-90-labelled Rituximab (Chimeric Anti CD-20 Antibody) in Patients with Relapsed and Refractory B Cell Non-Hodgkins Lymphoma
Current Radiopharmaceuticals Induction of Apoptosis via the Modulation of Reactive Oxygen Species (ROS) Production in the Treatment of Myeloid Leukemia
Current Pharmaceutical Biotechnology Cancer Therapy: Targeting Cell Cycle Regulators
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Targeting of Cancers with Loss of PTEN Function
Current Drug Targets Rho-Signaling Pathways in Chronic Myelogenous Leukemia
Cardiovascular & Hematological Disorders-Drug Targets Immune Modulation of Asian Folk Herbal Medicines and Related Chemical Components for Cancer Management
Current Medicinal Chemistry Post-Wortmannin Era: Novel Phosphoinositide 3-Kinase Inhibitors with Potential Therapeutic Applications
Current Enzyme Inhibition Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents
Current Protein & Peptide Science The Immunoproteasome as a Therapeutic Target for Hematological Malignancies
Current Cancer Drug Targets The Stem Cell Niche as a Pharmaceutical Target for Prevention of Skeletal Metastases
Anti-Cancer Agents in Medicinal Chemistry Diagnosis and Management of Lynch Syndrome
Recent Patents on Regenerative Medicine Medical Applications of Hyperthermia Based on Magnetic Nanoparticles
Recent Patents on Biomedical Engineering (Discontinued) Flavonoid Derivatives Targeting BCR-ABL Kinase: Semisynthesis, Molecular Dynamic Simulations and Enzymatic Inhibition
Current Topics in Medicinal Chemistry Multiple Roles for Glycogen Synthase Kinase-3 as a Drug Target in Alzheimers Disease
Current Drug Targets Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells
Current Pharmaceutical Biotechnology